Comparative Pharmacology
Head-to-head clinical analysis: FULVICIN P G 165 versus MICONAZOLE 7 COMBINATION PACK.
Peer-Reviewed Evidence
Head-to-head clinical analysis: FULVICIN P G 165 versus MICONAZOLE 7 COMBINATION PACK.
FULVICIN P/G 165 vs MICONAZOLE 7 COMBINATION PACK
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Griseofulvin binds to and disrupts microtubule function by inhibiting spindle formation and mitosis in dermatophytes, leading to inhibition of fungal cell division.
Miconazole is an imidazole antifungal agent that inhibits the synthesis of ergosterol, a key component of fungal cell membranes, by inhibiting the enzyme lanosterol 14α-demethylase. This leads to increased membrane permeability and leakage of cellular contents, resulting in fungal cell death.
165 mg orally once daily.
Miconazole 200 mg vaginal suppository once daily at bedtime for 7 days, plus miconazole 2% cream applied intravaginally once daily at bedtime for 7 days.
None Documented
None Documented
Terminal elimination half-life is approximately 9-24 hours; dependent on formulation and absorption rate. Steady-state achieved within 4-5 days.
Terminal elimination half-life is approximately 24-30 hours after systemic absorption. Clinically, this supports once-daily dosing for the vaginal route.
Primarily renal excretion of metabolites; <1% excreted unchanged. Biliary/fecal elimination accounts for ~30% of metabolites.
Miconazole is primarily metabolized in the liver, with metabolites and unchanged drug excreted in feces (50-70%) and urine (10-20%). Biliary excretion is a minor route.
Category C
Category A/B
Antifungal
Antifungal